Daiichi Sankyo

Stamp with blue ink that says FDA Approved
Pharma

Merck KGaA's Pimjetmi wins FDA approval in rare tumor disorder

The FDA's approval was based on phase 3 data in which Pimjetmi demonstrated a 56% response rate and no liver toxicity incidents.
Donavyn Coffey Nov 10, 2026 5:45pm
topic report
National Breast Cancer Awareness Month pink ribbon
Favicon Fierce Biotech

After Enhertu: The slow hunt for next-gen HER2 breast cancer drugs

Oct 28, 2026 9:00am
Stamp with blue ink that says FDA Approved

Cosette lands FDA approval for Evoxac liquid in Sjögren’s

Oct 20, 2026 11:22am
Asia

AZ-Summit, Novo-Hengrui, Merck—Fierce Pharma Asia

Oct 2, 2026 9:35am
football goalpost touchdown score

AZ, Daiichi's Enhertu nabs long-sought NHS blessing from NICE

Sep 16, 2026 7:30pm
Enhertu

Increased deaths shadow Enhertu’s first-line lung cancer data

Sep 13, 2026 7:00pm